Strattera is primarily prescribed for which condition?

Strattera, known generically as atomoxetine, is primarily prescribed for attention-deficit/hyperactivity disorder (ADHD). It is a selective norepinephrine reuptake inhibitor that is non-stimulant, making it a unique option in the treatment of ADHD compared to traditional stimulant medications. Strattera works by increasing the levels of norepinephrine in the brain, which can help improve attention, focus, and impulse control in individuals with ADHD.

The effectiveness of Strattera specifically in treating ADHD is supported by a considerable body of research, highlighting its role in alleviating symptoms related to attention deficits, hyperactivity, and impulsivity in both children and adults. Unlike stimulants, which can have a rapid onset of action, Strattera may take several weeks to reach its full effect, but it is beneficial for individuals who may not tolerate stimulant medications or who have a history of substance use disorders. This makes Strattera a valuable option in the comprehensive management of ADHD.